Chugai Pharmaceutical Co., Ltd. · TSE:4519

Chugai Pharmaceutical — Q1 2011 Earnings Presentation

14 slides from Chugai Pharmaceutical's earnings presentation, Apr 21, 2011

  1. Slide 1: FY2011 1Q Consolidated Financial Overview

    FY2011 1Q Consolidated C lid t d Financial Fi i l Overview O i CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President and CFO Yoshio Itaya April 21, 2011

  2. Slide 2: Forward-Looking Statements

    FY2011 1Q Consolidated Financial Overview F Forward-Looking d L ki St Statements t t This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect fl t the th Company’s C ’ currentt analy

  3. Slide 3: Summary

    FY2011 1Q Consolidated Financial Overview Summary  Revenues 85.7 billion JPY: slight g decline due to Tamiflu ((-1.6%)) • Tamiflu: stockpiling sales closing out • Domestic sales excl. Tamiflu: strong growth in Oncology and Bone & Joint >7% • Overseas sales: >20% decrease due to stronger JPY and imp

  4. Slide 4: Financial Overview Jan-Mar

    Year on Year FY2011 1Q Consolidated Financial Overview Financial Overview Jan Mar Jan-Mar (Billion JPY) 2010 2011 (Billion JPY) As % of As % of Jan-Mar Revenues Jan-Mar Revenues Variance  Sales excl. Tamiflu % Domestic +2.2 Revenues 87.1 85.7 -1.4 -1.6 Overseas -1.5 Sales 86.2 80.4 -5.8 -6.7  Sale

  5. Slide 5: Sales (excl. Tamiflu) Jan-Mar

    Year on Year FY2011 1Q Consolidated Financial Overview Sales (excl (excl. Tamiflu) Jan-Mar Jan Mar (Billion JPY) Sales (excl. Tamiflu) 76.2 (+0.8, +1.1%) 75.4 Overseas 7.4 -1.5, -20.3% 5.9 Epogin Avastin -1.2 (7.5) (12.5) +2.2 Others 8.3 8.3 ±0, ±0.0% 11.8% Neutrogin Actemra 12.2% 5.5 7.8% ((Oversea

  6. Slide 6: Tamiflu Sales Performance

    FY2011 1Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales (Billion JPY) FY2005.12 FY2006.12 FY2007.12 FY2008.12 FY2009.12 FY2010.12 FY2011.12 C a se s p e r Seasonal se n ti n e l * Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Ju

  7. Slide 7: Operating Income Jan-Mar

    Year on Year FY2011 1Q Consolidated Financial Overview Operating Income Jan-Mar Jan Mar 2010 2011 (Billion JPY) (Billion JPY) Variance Jan-Mar Jan-Mar (%) Revenues 87.1 85.7 -1.4 -1.6 Decrease in SG&A Cost of Sales 41.1 35.1 -6.0 -14.6 (excl. R&D) exp. Gross Profit 46.0 50.6 +4.6 +10.0 Increase in O

  8. Slide 8: Impact of the Great East Japan Earthquake

    Revision of Forecast FY2011 1Q Consolidated Financial Overview Impact of the Great East Japan Earthquake  Damage • Utsunomiya Plant (Chugai Pharma Manufacturing Co., LTD.) was severely damaged. • Minor damage g was reported p from other p plants,, logistics g centers,, R&D labs, Sendai Branch and K

  9. Slide 9: Revision of Forecast

    Revision of Forecast FY2011 1Q Consolidated Financial Overview Revision of Forecast  Limited Li it d tto E Extraordinary t di L Loss Sales and Operating Income guidance remains unchanged. While uncertainties remain such as power supply, no major impact on Sales is expected. • Full-scale production

  10. Slide 10: Revision of Forecast Overview

    Revision of Forecast FY2011 1Q Consolidated Financial Overview Overview A t l Actual F Forecast t Jan-Jun J J 2011 F Forecast t Jan-Dec J D 2011 (Billion JPY) 2011 Original Revised Original Revised variance variance Jan-Mar (Feb. 2) (Apr. 21) (Feb. 2) (Apr. 21) Revenues 85 7 85.7 190 0 190.0 190 0 1

  11. Slide 11: Overview of Development Pipeline

    Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Department Manager R&D Portfolio Management Dept. Hisanori Takanashi April 21, 2011

  12. Slide 12: Development Status - Oncology, Bone & Joint

    Overview of Development Pipeline Development Status - Oncology, Oncology Bone & Joint In- Edirol (ED-71): Osteoporosis house Launched in Apr. 2011 In- Actemra (US): sJIA house Approved in Apr Apr. 2011 In- Xeloda: Gastric cancer li licensedd Approved in Feb. 2011 In- licensed H Herceptin: ti G Gastr

  13. Slide 13: Development Status - Transplant, Immunology, Infectious diseases and others

    Overview of Development Pipeline Development p Status – Transplant, Immunology, Infectious diseases and others In- licensed Pegasys: Hepatitis B Designated as priority review subject in Apr. 2011 In- licensed taspoglutide (RG1583): Type Ⅱ diabetes Development suspended * Roche returned development l

  14. Slide 14: Contacts: Corporate Communications Dept.

    Contacts: Corporate Communications Dept. Corporate Communications Group Tel: +81 (0)3-3273-0881 (0)3 3273 0881 Fax: +81 (0)3 (0)3-3281-6607 3281 6607 e-mail: [email protected] Hitoshi Aikawa, Shinichi Hirose, Hiroshi Araki, Kae Miyata Investor es o Relations ea o sG Group oup Tel: +81 (0)3-3273-

Chugai Pharmaceutical — Q1 2011 Earnings Presentation on 6ix